Reuters reported that Pfizer. has released the results of the COVID-19 vaccine trial Among adolescents aged 12 to 15, the company’s vaccine was 100% effective at protecting against COVID-19 for up to four months after receiving the second dose.
The release of Pfizer’s data reflects the effectiveness of the COVID-19 vaccine. that it is appropriate for long-term injections to adolescents aged 12 to 15 years, which Pfizer prepares to bring this latest data set Filed with the U.S. Food and Drug Administration (FDA), as well as food and drug regulators in many countries around the world. To request approval for the use of the COVID-19 vaccine in the amount of 30 micrograms for those aged 12 years and over.
The vaccine against COVID-19 Pfizer’s brand name was FDA-approved for use in teenagers aged 12-15 last month, and was approved for use in people aged 16 and over last month. last Aug.
.
